Physician profile
Amber Maison
NPI 1962986349
$4,125.05
in general payments reported to CMS, 2019-2025
32 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $824 · 2023: $357 · 2024: $1,102 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.54 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,267.79 | 2022-2025 | |
| Janssen Biotech, INC. | $391.76 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $339.41 | 2021-2022 | |
| Genzyme Corporation | $262.82 | 2024-2025 | |
| Allergan, INC. | $233.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $200.39 | 2024-2025 | Dupixent, Libtayo |
| Novo Nordisk INC | $172.96 | 2021-2022 | |
| Amgen INC. | $165.69 | 2022-2025 | Otezla, Otezla, Evenity |
| Arcutis Biotherapeutics, INC. | $136.03 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $121.68 | 2024-2025 | |
| Nevro Corp. | $87.99 | 2021-2022 | |
| Hill Dermaceuticals, INC. | $72.82 | 2024-2025 | Tolak |
| Ucb, INC. | $67.96 | 2024-2025 | Bimzelx |
| Biohaven Pharmaceutical Holding Company LTD. | $61.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $59.49 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.38 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $57.30 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $48.35 | 2025 | Nemluvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.22 | 2022-2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $29.89 | 2022-2023 | Mounjaro |
| Kyowa Kirin, INC. | $29.53 | 2025 | |
| Fidia Pharma USA INC. | $25.20 | 2025 | |
| Boston Scientific Corporation | $24.61 | 2025 | General - Pain Management |
| Botanix Sb INC | $24.34 | 2025 | Sofdra |
| Incyte Corporation | $19.93 | 2024 | Opzelura |
| Organogenesis INC. | $19.34 | 2025 | Puraply Wound Matrix |
| Vanda Pharmaceuticals INC. | $18.83 | 2022 | |
| Dermavant Sciences, INC. | $18.61 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $17.92 | 2025 | Ycanth |
| Biohaven Pharmaceuticals, INC. | $15.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.39 | 2022 | |
| Impulse Dynamics (USA) INC. | $13.21 | 2023 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Maison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.